ELTX (Elicio Therapeutics) OCF Yield %: -50.40 (As of Jun. 29, 2026)


ELTX Elicio Therapeutics Inc ELTX
32 GF Score
Price $4.00
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics OCF Yield %?

Elicio Therapeutics ELTX +0.38% 32 OCF Yield % is -50.40 as of Jun. 29, 2026. GuruFocus rates ELTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Elicio Therapeutics ranks worse than 83.55% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Elicio Therapeutics's Trailing 12-Month Cash Flow from Operations is $-38.48 Mil, and Market Cap is $76.35 Mil. Therefore, Elicio Therapeutics's OCF Yield % for today is -50.40%.

The historical rank and industry rank for Elicio Therapeutics's OCF Yield % or its related term are showing as below:

ELTX' s OCF Yield % Range Over the Past 10 Years
Min: -51.49   Med: 0   Max: -48.35
Current: -50.4


During the past 7 years, the highest OCF Yield % of Elicio Therapeutics was -48.35%. The lowest was -51.49%. And the median was %.

ELTX's OCF Yield % is ranked worse than
83.55% of 1416 companies
in the Biotechnology industry
Industry Median: -8.23 vs ELTX: -50.40

Elicio Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Elicio Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Elicio Therapeutics OCF Yield % Related Terms


Elicio Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics OCF Yield % Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 -40.82 -65.90 -26.08

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.15 -28.51 -23.49 -19.19 -23.38

ELTX vs GOSS, GANX, ACET: OCF Yield % Comparison

For the Biotechnology subindustry, Elicio Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicio Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's OCF Yield % falls into.


ELTX
32GF Score
Elicio Therapeutics Inc ELTX
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Elicio Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-36.952 / 141.688
=-26.08%

Elicio Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-11.645 * 4 / 199.2616
=-23.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -50.40 mean?
Elicio Therapeutics (ELTX) has a OCF Yield % of -50.40 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Elicio Therapeutics and its competitors. According to the industry distribution chart, Elicio Therapeutics ranks #1183 out of 1416 companies in the Biotechnology industry, placing it in the top 83.5%.
Is Elicio Therapeutics' OCF Yield % too high?
Elicio Therapeutics' current OCF Yield % is -50.40. Based on the distribution chart, Elicio Therapeutics ranks #1183 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' OCF Yield % compare to GOSS and GANX?
According to the Biotechnology industry distribution chart, Elicio Therapeutics ranks #1183 out of 1416 companies for OCF Yield %. This places Elicio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current OCF Yield % is -50.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current OCF Yield % of -50.40. The current OCF Yield % is -50.40. Elicio Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current OCF Yield % is -50.40 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
32GF Score

Get the complete analysis for ELTX

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price